Compare Stocks: UCBJF, PFE, BMY, and SNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$66.07 +2.2%	$59.94	$42.52 ▼ $68.10	$132.02B	0.22	12.25 million shs	9.41 million shs
PFE Pfizer	$27.30 +1.6%	$25.18	$23.58 ▼ $28.75	$152.69B	0.34	39.50 million shs	34.63 million shs
SNY Sanofi	$44.97 +1.3%	$43.34	$40.89 ▼ $52.68	$106.00B	0.35	3.39 million shs	3.17 million shs
UCBJF UCB	$254.59	$284.95	$219.50 ▼ $345.39	$48.12B	0.47	767 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+2.10%	+3.78%	+8.83%	+13.03%	+37.11%
PFE Pfizer	+1.54%	+2.57%	+8.83%	+5.89%	+8.88%
SNY Sanofi	+1.26%	+3.24%	+0.69%	+0.67%	-9.77%
UCBJF UCB	0.00%	-3.70%	-6.83%	-9.58%	+9.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$66.07 +2.2%	$59.94	$42.52 ▼ $68.10	$132.02B	0.22	12.25 million shs	9.41 million shs
PFE Pfizer	$27.30 +1.6%	$25.18	$23.58 ▼ $28.75	$152.69B	0.34	39.50 million shs	34.63 million shs
SNY Sanofi	$44.97 +1.3%	$43.34	$40.89 ▼ $52.68	$106.00B	0.35	3.39 million shs	3.17 million shs
UCBJF UCB	$254.59	$284.95	$219.50 ▼ $345.39	$48.12B	0.47	767 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+2.10%	+3.78%	+8.83%	+13.03%	+37.11%
PFE Pfizer	+1.54%	+2.57%	+8.83%	+5.89%	+8.88%
SNY Sanofi	+1.26%	+3.24%	+0.69%	+0.67%	-9.77%
UCBJF UCB	0.00%	-3.70%	-6.83%	-9.58%	+9.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.52	Moderate Buy	$66.06	-0.02% Downside
PFE Pfizer	2.19	Hold	$28.28	3.60% Upside
SNY Sanofi	2.40	Hold	$49.50	10.07% Upside
UCBJF UCB	2.75	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest UCBJF, PFE, BMY, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $31.00
8/5/2026	BMY Bristol Myers Squibb	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Strong-Buy
8/5/2026	BMY Bristol Myers Squibb	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy
8/5/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/5/2026	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/5/2026	BMY Bristol Myers Squibb	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/5/2026	BMY Bristol Myers Squibb	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/5/2026	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/5/2026	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00
8/3/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/3/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$49.19B	2.74	$8.42 per share	7.85	$9.09 per share	7.27
PFE Pfizer	$62.58B	2.49	$4.48 per share	6.09	$15.26 per share	1.79
SNY Sanofi	$49.35B	2.21	$7.26 per share	6.19	$33.27 per share	1.35
UCBJF UCB	$5.27B	9.14	$10.94 per share	23.28	$50.52 per share	5.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$4.54	14.55	10.26	0.17	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
PFE Pfizer	$7.77B	$0.76	35.91	9.32	N/A	6.80%	19.63%	8.46%	11/3/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	23.54	8.63	1.09	8.66%	14.19%	7.95%	10/23/2026 (Estimated)
UCBJF UCB	$371.23M	N/A	N/A	36.06	N/A	N/A	N/A	N/A	N/A

Latest UCBJF, PFE, BMY, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	PFE Pfizer	$0.6820	$0.77	+$0.0880	-$0.04	$14.40 billion	$15.03 billion
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	3.81%	+1.61%	55.51%	17 Years
PFE Pfizer	$1.72	6.30%	-13.20%	226.32%	16 Years
SNY Sanofi	$1.76	3.91%	+6.46%	92.15%	N/A
UCBJF UCB	N/A	N/A	N/A	N/A	N/A

Latest UCBJF, PFE, BMY, and SNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.01%	7/24/2026	7/24/2026	9/1/2026
6/17/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.34%	7/2/2026	7/2/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	1.89	1.53	1.38
PFE Pfizer	0.71	1.27	0.96
SNY Sanofi	0.21	0.99	0.64
UCBJF UCB	0.33	1.19	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
PFE Pfizer	68.36%
SNY Sanofi	14.03%
UCBJF UCB	N/A

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
PFE Pfizer	0.62%
SNY Sanofi	1.00%
UCBJF UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
UCBJF UCB	9,083	189.02 million	N/A	Not Optionable

UCBJF, PFE, BMY, and SNY Headlines

Recent News About These Companies

UCB SA (OTCMKTS:UCBJF) Receives Average Rating of "Moderate Buy" from Brokerages

August 16 at 4:15 AM | americanbankingnews.com

Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection

August 3, 2026 | tipranks.com

Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion

May 3, 2026 | reuters.com

Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B

April 17, 2026 | seekingalpha.com

Belgium's UCB in autoimmune drug deal with Antengene

March 3, 2026 | reuters.com

Day by Day maintains UCB (UCBJF) buy recommendation

December 17, 2025 | msn.com

UCB price target raised to EUR 300 from EUR 230 at JPMorgan

December 8, 2025 | msn.com

UCB removed from European Conviction List at Goldman Sachs

November 4, 2025 | msn.com

UCB assumed with an Underperform at Jefferies

October 27, 2025 | msn.com

UCB announces new three-year data from Phase 3 trials on BIMZELX

October 26, 2025 | msn.com

United Community Banks, Inc. (UCB) Q3 2025 Earnings Call Transcript

October 22, 2025 | seekingalpha.com

UCB price target raised to EUR 290 from EUR 220 at Berenberg

October 14, 2025 | msn.com

UCB price target raised to EUR 285 from EUR 250 at Deutsche Bank

October 6, 2025 | msn.com

MoonLake rebounds despite downgrades prompted by trial setback

September 30, 2025 | msn.com

UCB price target raised to EUR 240 from EUR 220 at Morgan Stanley

September 8, 2025 | msn.com

UCB SA (UCBJF) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

United Community Banks, Inc. (UCB) Q2 2025 Earnings Call Transcript

July 23, 2025 | seekingalpha.com

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

May 20, 2025 | finance.yahoo.com

United Community Banks, Inc. (UCB) Q1 2025 Earnings Call Transcript

April 22, 2025 | seekingalpha.com

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

April 3, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UCBJF, PFE, BMY, and SNY Company Descriptions

Bristol Myers Squibb NYSE:BMY

$66.07 +1.44 (+2.23%)

Closing price 08/18/2026 03:59 PM Eastern

Extended Trading

$66.20 +0.13 (+0.20%)

As of 05:08 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Pfizer NYSE:PFE

$27.30 +0.43 (+1.58%)

Closing price 08/18/2026 03:59 PM Eastern

Extended Trading

$27.21 -0.09 (-0.31%)

As of 05:31 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi NASDAQ:SNY

$44.97 +0.56 (+1.26%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$45.14 +0.16 (+0.37%)

As of 05:30 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

UCB OTCMKTS:UCBJF

$254.59 0.00 (0.00%)

As of 08/17/2026

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UCBJF, PFE, BMY, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UCBJF, PFE, BMY, and SNY Earnings

Compare Dividends

Latest UCBJF, PFE, BMY, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UCBJF, PFE, BMY, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UCBJF, PFE, BMY, and SNY Company Descriptions

Bristol Myers Squibb NYSE:BMY

Pfizer NYSE:PFE

Sanofi NASDAQ:SNY

UCB OTCMKTS:UCBJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UCBJF, PFE, BMY, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UCBJF, PFE, BMY, and SNY Earnings

Compare Dividends

Latest UCBJF, PFE, BMY, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UCBJF, PFE, BMY, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UCBJF, PFE, BMY, and SNY Company Descriptions

Bristol Myers Squibb NYSE:BMY

Pfizer NYSE:PFE

Sanofi NASDAQ:SNY

UCB OTCMKTS:UCBJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools